We further conducted multiplex immunohistochemistry (mIHC) on 36 tumor samples to track SELP+ HEVs and STMN1+ cECs in the TME before and after treatment, aiming to validate our aforementioned findings. The gene discussed is STMN1; the disease is neoplasm.